NCT02573857View on ClinicalTrials.gov

A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Malaria
Interventions
DRUG

DSM265

Oral suspension from bulk powder

DRUG

OZ439

Oral suspension from powder in a bottle

Trial Locations (1)

4006

Q-Pharm Clinics, Herston

Sponsors
All Listed Sponsors
collaborator

Clinical Network Services (CNS) Pty Ltd

INDUSTRY

collaborator

Q-Pharm Pty Limited

INDUSTRY

collaborator

Queensland Institute of Medical Research

OTHER

lead

Medicines for Malaria Venture

OTHER

NCT02573857 - A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection | Biotech Hunter | Biotech Hunter